National Meeting on ZADAXIN(R) Use in Cancer Held in China; - New Liver Cancer One-Year Follow-Up Data Presented -

Apr 23, 2001, 01:00 ET from SciClone Pharmaceuticals

    SAN MATEO, Calif., April 23 /PRNewswire Interactive News Release/ --
 SciClone Pharmaceuticals (Nasdaq:   SCLN) announced that approximately
 800 cancer researchers and physicians, including China's top oncologists,
 gathered on Saturday, April 21st, at the Shanghai International Convention
 Center for the "National ZADAXIN(R) Meeting on Cancer" in the People's
 Republic of China.  More than 40 papers and abstracts were submitted
 containing data resulting from cancer research and clinical experience using
 ZADAXIN, SciClone's immune system enhancer (ISE).
     The meeting covered three broad topics, each the subject of a formal
 session: 1) treatments for cancer using ZADAXIN in combination with
 chemotherapy, surgery and other interventions; 2) use of ZADAXIN in the
 specific treatment of hepatocellular carcinoma (HCC); and 3) use of ZADAXIN in
 the prevention of chemotherapeutic adverse effects.
     During the featured second session Dr. W.J. Zhang presented new one-year
 follow-up data from a study of HCC patients treated with ZADAXIN plus
 transarterial chemoembolization (TACE) led by Dr. Z.S. Li of Changhai Hospital
 and The Second Military Medical University.  In this study, the combination
 treatment resulted in statistically significant improvement in survival rates
 at 6, 9 and 12 months following treatment of 91%, 88% and 78% respectively,
 compared to rates of 77%, 58% and 46% in a matched historical control group
 using TACE alone.
     "Cancer represents the next level of ZADAXIN development in the U.S. and
 Europe with much of the pioneering research being done in our current
 markets," said Donald R. Sellers, SciClone's President and Chief Executive
 Officer.  "China has an internationally recognized oncology research community
 and important early clinical data has emerged from there.  Attending the
 meeting, I was particularly interested in the third session.  Acceptance of
 ZADAXIN as a significant part of combination therapies for cancer treatment in
 China can be a key driver for continued sales growth in that country and in
 markets worldwide."
     The Chinese cancer symposium was sponsored by SciClone as part of the
 Company's worldwide cancer clinical program for ZADAXIN, which includes U.S.
 phase 2 liver cancer trials, a phase 2 melanoma trial in Australia, and other
 clinical investigations in Italy and China.
     ZADAXIN has been administered to over 3,000 subjects in over 70 clinical
 trials covering a broad range of diseases and to an estimated 7,000 patients
 commercially with virtually no serious drug related adverse events or
 toxicities.  ZADAXIN is approved for sale in 21 countries, principally for the
 treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for
 patients with weakened immune systems.  ZADAXIN is currently in a phase
 3 program in the U.S. in combination with Pegasys(R) (pegylated interferon
 alfa-2a) for the treatment of hepatitis C, in a phase 2 program in combination
 with lamivudine for the treatment of hepatitis B and in a phase 2 trial for
 the treatment of liver cancer.  In Europe, a phase 3 ZADAXIN program will
 complement the Company's U.S. hepatitis C program.  ZADAXIN is also in
 clinical trials in Japan and Australia.
     SciClone Pharmaceuticals is a global specialty pharmaceutical company that
 develops and commercializes novel medicines for the treatment of a broad range
 of the world's most serious diseases.  The Company is currently targeting
 malignant melanoma, liver cancer, hepatitis B, hepatitis C, HIV,
 drug-resistant tuberculosis and cystic fibrosis.  Press releases and corporate
 information from SciClone Pharmaceuticals are available on the Internet at
 www.sciclone.com or by calling the Company's Investor Relations Department at
 800/724-2566.  SciClone's Common Stock is listed on The Nasdaq National
 Market(R) under the symbol SCLN.
     The information in this press release includes certain forward-looking
 statements concerning the Company's current expectations regarding future
 events.  This includes, the ongoing and prospective development and
 commercialization of ZADAXIN immunotherapy for cancer, the continued growth in
 ZADAXIN sales in China and the timeline of ZADAXIN clinical trials in
 hepatitis B, hepatitis C and cancer.  Due to market factors and the nature of
 product development and the regulatory approval process, the forward-looking
 statements contained in this press release are subject to risks and
 uncertainties, including those reflected in the Company's filings with the
 Securities and Exchange Commission, particularly the Company's Annual Report
 on Form 10-K for the year ended December 31, 2000.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X73609684
 
 

SOURCE SciClone Pharmaceuticals
    SAN MATEO, Calif., April 23 /PRNewswire Interactive News Release/ --
 SciClone Pharmaceuticals (Nasdaq:   SCLN) announced that approximately
 800 cancer researchers and physicians, including China's top oncologists,
 gathered on Saturday, April 21st, at the Shanghai International Convention
 Center for the "National ZADAXIN(R) Meeting on Cancer" in the People's
 Republic of China.  More than 40 papers and abstracts were submitted
 containing data resulting from cancer research and clinical experience using
 ZADAXIN, SciClone's immune system enhancer (ISE).
     The meeting covered three broad topics, each the subject of a formal
 session: 1) treatments for cancer using ZADAXIN in combination with
 chemotherapy, surgery and other interventions; 2) use of ZADAXIN in the
 specific treatment of hepatocellular carcinoma (HCC); and 3) use of ZADAXIN in
 the prevention of chemotherapeutic adverse effects.
     During the featured second session Dr. W.J. Zhang presented new one-year
 follow-up data from a study of HCC patients treated with ZADAXIN plus
 transarterial chemoembolization (TACE) led by Dr. Z.S. Li of Changhai Hospital
 and The Second Military Medical University.  In this study, the combination
 treatment resulted in statistically significant improvement in survival rates
 at 6, 9 and 12 months following treatment of 91%, 88% and 78% respectively,
 compared to rates of 77%, 58% and 46% in a matched historical control group
 using TACE alone.
     "Cancer represents the next level of ZADAXIN development in the U.S. and
 Europe with much of the pioneering research being done in our current
 markets," said Donald R. Sellers, SciClone's President and Chief Executive
 Officer.  "China has an internationally recognized oncology research community
 and important early clinical data has emerged from there.  Attending the
 meeting, I was particularly interested in the third session.  Acceptance of
 ZADAXIN as a significant part of combination therapies for cancer treatment in
 China can be a key driver for continued sales growth in that country and in
 markets worldwide."
     The Chinese cancer symposium was sponsored by SciClone as part of the
 Company's worldwide cancer clinical program for ZADAXIN, which includes U.S.
 phase 2 liver cancer trials, a phase 2 melanoma trial in Australia, and other
 clinical investigations in Italy and China.
     ZADAXIN has been administered to over 3,000 subjects in over 70 clinical
 trials covering a broad range of diseases and to an estimated 7,000 patients
 commercially with virtually no serious drug related adverse events or
 toxicities.  ZADAXIN is approved for sale in 21 countries, principally for the
 treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for
 patients with weakened immune systems.  ZADAXIN is currently in a phase
 3 program in the U.S. in combination with Pegasys(R) (pegylated interferon
 alfa-2a) for the treatment of hepatitis C, in a phase 2 program in combination
 with lamivudine for the treatment of hepatitis B and in a phase 2 trial for
 the treatment of liver cancer.  In Europe, a phase 3 ZADAXIN program will
 complement the Company's U.S. hepatitis C program.  ZADAXIN is also in
 clinical trials in Japan and Australia.
     SciClone Pharmaceuticals is a global specialty pharmaceutical company that
 develops and commercializes novel medicines for the treatment of a broad range
 of the world's most serious diseases.  The Company is currently targeting
 malignant melanoma, liver cancer, hepatitis B, hepatitis C, HIV,
 drug-resistant tuberculosis and cystic fibrosis.  Press releases and corporate
 information from SciClone Pharmaceuticals are available on the Internet at
 www.sciclone.com or by calling the Company's Investor Relations Department at
 800/724-2566.  SciClone's Common Stock is listed on The Nasdaq National
 Market(R) under the symbol SCLN.
     The information in this press release includes certain forward-looking
 statements concerning the Company's current expectations regarding future
 events.  This includes, the ongoing and prospective development and
 commercialization of ZADAXIN immunotherapy for cancer, the continued growth in
 ZADAXIN sales in China and the timeline of ZADAXIN clinical trials in
 hepatitis B, hepatitis C and cancer.  Due to market factors and the nature of
 product development and the regulatory approval process, the forward-looking
 statements contained in this press release are subject to risks and
 uncertainties, including those reflected in the Company's filings with the
 Securities and Exchange Commission, particularly the Company's Annual Report
 on Form 10-K for the year ended December 31, 2000.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X73609684
 
 SOURCE  SciClone Pharmaceuticals

RELATED LINKS

http://www.biospace.com/sciclone/